SEC Form SC 13G filed by ENDRA Life Sciences Inc.

3/10/23 12:18:14 PM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $NDRA alert in real time by email

SC 13G 1 ffsc13g.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENDRA LIFE SCIENCES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29273B02 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant* to which this Schedule is filed: [ x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 29273B02 1. Names of Reporting Persons. Michael Bryan, Sr. 2. Check the Appropriate Box if a Member of a Group (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization New Hampshire Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 192,500 6. Shared Voting Power 7. Sole Dispositive Power 192,500 8. Shared Dispositive Power 9. Aggregate Amount Beneficially Owned by Each Reporting * Person 192,500 10. Check if the Aggregate Amount in Row (9) Excludes * Certain Shares 11. Percent of Class Represented by Amount in Row (9) 6.1% 12. Type of Reporting Person IN ITEM 1. (a) Name of Issuer: ENDRA LIFE SCIENCES, INC. (b) Address of Issuer's Principal Executive Offices: 3600 Green Court, Suite 350 Ann Arbor, Michigan 48105 ITEM 2. (a) Name of Person Filing: Michael Bryan, Sr. (b) Address of Principal Business Office, or if None,* Residence: 51 Wentworth Rd Rye, NH 03870 (c) Citizenship: New Hampshire (d) Title of Class of Securities: Common Stock, $0.0001 par value per share (e) CUSIP Number: 29273B02 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b)* OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a)[_] Broker or dealer registered under Section 15 of the* Act (15 U.S.C. 78o). (b)[_] Bank as defined in Section 3(a)(6) of the Act (15* U.S.C. 78c). (c)[_] Insurance company as defined in Section 3(a)(19) of * the Act (15 U.S.C. 78c). (d)[_] Investment company registered under Section 8 of the* Investment Company Act of 1940 (15 U.S.C. 80a-8). (e)[_] An investment adviser in accordance with ss.240.13d-* 1(b)(1)(ii)(E); (f)[_] An employee benefit plan or endowment fund in* accordance with ss.240.13d-1(b)(1)(ii)(F); (g)[_] A parent holding company or control person in* accordance with ss.240.13d-1(b)(1)(ii)(G); (h)[_] A savings associations as defined in Section 3(b) of* the Federal Deposit Insurance Act (12 U.S.C. 1813); (i)[_] A church plan that is excluded from the definition of* an investment company under section 3(c)(14) of the Investment* Company Act of 1940 (15 U.S.C. 80a-3); (j)[_] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J). ITEM 4. OWNERSHIP. (a) Amount beneficially owned: 192,500 (b) Percent of class: 6.1% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote 192,500 (ii) Shared power to vote or to direct the vote 0 (iii) Sole power to dispose or to direct the disposition of 192,500 (iv) Shared power to dispose or to direct the disposition of 0 ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. If this statement is being filed to report the fact that as of * the date hereof the reporting person has ceased to be the * beneficial owner of more than five percent of the class of * securities, check the following [ ]. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF* OF ANOTHER PERSON. Not Applicable ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY * WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY * THE PARENT HOLDING COMPANY. Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE * GROUP. Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. ITEM 10. CERTIFICATIONS. By signing below, I certify that, to the best of my knowledge * and belief, the securities referred to above were acquired and * are held in the ordinary course of business and were not * acquired and not held for the purpose of or with the effect of * changing or influencing the control of the issuer of the * securities and were not acquired and are not held in * connection with or as a participant in any transaction having * such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and * belief, I certify that the information set forth in this * statement is true, complete and correct. March 9, 2023 (Date) /s/ Michael Bryan, Sr. (Signature) Michael Bryan, Sr./ Investor (Name/Title)

Get the next $NDRA alert in real time by email

SEC Form SC 13G filed by ENDRA Life Sciences Inc.

3/10/23 12:18:14 PM ET

$NDRA

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $NDRA alert in real time by email

SEC Form SC 13G filed by ENDRA Life Sciences Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NDRA

SEC Form SC 13G filed by ENDRA Life Sciences Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NDRA

$NDRA
Insider Trading

Director Digiandomenico Anthony was granted 70,822 shares, increasing direct ownership by 1,301% to 76,265 units (SEC Form 4)

Director Basenese Lou was granted 5,384 shares, increasing direct ownership by 538,400% to 5,385 units (SEC Form 4)

Director Harsh Michael was granted 5,384 shares, increasing direct ownership by 269,200% to 5,386 units (SEC Form 4)

$NDRA
SEC Filings

ENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form SCHEDULE 13D filed by ENDRA Life Sciences Inc.

SEC Form 424B4 filed by ENDRA Life Sciences Inc.

$NDRA
Insider Purchases

Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

$NDRA
Press Releases

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

$NDRA
Leadership Updates

ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

$NDRA
Financials

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

$NDRA
Large Ownership Changes